Skip to main content

Vera Therapeutics, Inc.

VERA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001831828

In the last 90 days, Vera Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 219 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Vera Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of VERA: Q3 2021 compared with Q4 2021
MeasureQ3 2021Of which not filed for Q4 2021Q4 2021Change
Holders31137+7
Shares14.7M1.34M14.1M+687.2K (+5.1%)
Value$252.4M$23.3M$374.9M+$145.8M (+63.6%)

1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held Vera Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to VERA in Q4 2021
InstitutionSharesValue% of portfolio
Kynam Capital Management, LP253,449$6.77M3.62%
International Biotechnology Trust PLC120,535$3.20M0.71%
Logos Global Management LP50,000$1.34M0.14%
Carnegie Mellon University32,120$858.0K0.34%
Nuveen Asset Management, LLC15,098$344.0K0.00%
Cambridge Trust Co9,887$264.0K0.01%
Jane Street Group, LLC8,287$221.0K0.00%

Sold out (0)

Institutions that held Vera Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

None.

Not filed for Q4 2021 yet (1)

Institutions that held Vera Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VERA in Q3 2021 that haven't filed for Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
KPCB XVI Associates, LLC1,343,152$23.3M